Original Research
US prescribers’ attitudes and perceptions about biosimilars
Page: 96-103
Author byline as per print journal: Ralph D McKibbin, MD; Michael S Reilly, Esq Introduction: In the United States (US), a legal framework for approving biosimilars was established via the… Read More »
Social trust and regional variation in the adoption of biosimilars in Italy and Germany
Author(s): Professor James C Robinson, PhD, MPH
Page: 89-95
Introduction/Study Objectives: Adoption of biosimilars has fallen below projections, despite the vigorous implementation of economic incentives, thereby highlighting the importance of behavioural factors such as social trust. This paper analyses… Read More »
A case study of AstraZeneca’s omeprazole/esomeprazole chiral switch strategy
Author(s): Federico J Piñeiro, Pharm, MPH, Fernández Argüelles Rogelio Alberto, Pharm, PhD
Page: 57-64
Author byline as per print journal: Federico J Piñeiro, Pharm, MPH; Fernández Argüelles Rogelio Alberto, Pharm, PhD Introduction/Objective: To describe the chiral switch, an evergreening strategy used by AstraZeneca to position… Read More »
On statistical evaluation for interchangeability of biosimilar products
Page: 51-6
Author byline as per print journal: Yuqi Li, BS Pharm; Shein-Chung Chow, PhD A biosimilar product is a biological product which is highly similar to an existing reference product in structure… Read More »
Extended stability of the trastuzumab biosimilar ABP 980 (KANJINTI™) in polyolefin bags and elastomeric devices
Page: 153-71
Author byline as per print journal: Lyndsay Davies1, PhD; Katie Milligan1, BSc; Mark Corris1, BSc; Ian Clarke1; Paul Dwyer1, MSc; Sarah Elizabeth Lee2, PhD; Jolene Teraoka3, BSc; Jill Crouse-Zeineddini3, PhD; Jane… Read More »
Reasons for patients’ generic drug switching at the pharmacy counter: a pilot study
Page: 119-22
Author byline as per print journal: Pieter J Glerum1,2, MSc; Mert Hayta1,3, PharmD, MSc; David M Burger4, PharmD, PhD; Cees Neef5, PharmD, PhD; Marcel L Bouvy3, PharmD, PhD; Marc Maliepaard1,6,… Read More »
Pharmacokinetics and bioequivalence of generic etoricoxib in healthy volunteers
Page: 113-8
Author byline as per print journal: Nishalini Harikrishnan1, BSc; Ka-Liong Tan2, DPhil; Kar Ming Yee3, BPharm; Alia Shaari Ahmad Shukri1, MSc; Nalla Ramana Reddy4, MBBS; Chuei Wuei Leong3, PhD Introduction/Study… Read More »
Variation in the prices of oncology medicines across Europe and the implications for the future
Page: 72-82
Author byline as per print journal: Brian Godman1,2,3, BSc, PhD; Steven Simoens4, MSc, PhD; Amanj Kurdi1,5, BSc, PhD; Gisbert Selke6; John Yfantopoulos7, PhD; Andrew Hill8, PhD; Jolanta Gulbinovič9, MD, PhD;… Read More »
Biosimilars in Saudi Arabia: a single-centre, open-label case series examining infliximab switching
Page: 68-71
Author byline as per print journal: Mansour Somaily1, MD; Hana Alahmari1, MD; Wejdan Abbag2; Shahenda Yousif4, MD; Nawar Tayfour4, MD; Nouf Almushayt2; Saleh Alhusayni3, MD; Saeed Almajadiah4, MD Background: A… Read More »
Summative usability evaluation of the YLB113 etanercept biosimilar autoinjector via simulation
Page: 61-7
Author byline as per print journal: Kelly Canham1, BSc Hons; Claire Newcomb2, MSc Introduction/Study Objectives: Etanercept is a tumour necrosis factor inhibitor indicated for the treatment of several inflammatory disorders.… Read More »